Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Pzena Focused Value strategy. This analysis is provided for institutional research purposes only and is not investment advice.
"Extreme index concentration around artificial intelligence capital expenditure creates generational mispricings across neglected cyclical and defensive franchises, offering substantial margin of safety in durable businesses trading well below normalized earnings power."
Pzena Focused Value Composite delivered a net return of 4.5% in the third quarter of 2026, advancing 13.5% net of fees year-to-date and outperforming the Russell 1000 Value Index quarterly return of 2.6%. The portfolio carries an active share of 95.2% across 36 holdings, trading at an undemanding valuation of 6.9x price to normalized earnings versus the benchmark multiple of 12.4x. Sector performance was led by information technology, health care, and industrials, whereas consumer discretionary and consumer staples detracted from absolute performance. The global macroeconomic environment remains challenged by rising bond yields, persistent inflation, and Middle East geopolitical tensions, yet broader equity market leadership has grown exceptionally concentrated in artificial intelligence infrastructure. Index concentration in a handful of mega-cap technology winners has left traditional benchmarks vulnerable and priced at elevated historical valuations. In contrast, valuation dispersion across unloved cyclicals, business services, and defensive value franchises has widened dramatically, offering an asymmetric entry point into companies where temporary operational headwinds or technological transition fears obscure underlying earnings power. During the quarter, the strategy initiated positions in Genpact, where concerns regarding artificial intelligence disintermediation of business process outsourcing were judged to be overstated, and global pharmaceutical leader Sanofi on attractive free cash flow yields supported by its core Dupixent franchise. The portfolio also expanded existing stakes in hospital operator Universal Health Services and life insurer Corebridge Financial. These purchases were funded by harvesting gains in Medicare Advantage insurer Humana, semiconductor supplier Skyworks Solutions, and pharmaceutical manufacturer Bristol Myers Squibb.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon